BusinessAdaptimmune Announces Initiation of Triple Tumor Study to Evaluate its SPEAR® T-Cell Therapy Targeting MAGE-A10By Nasdaq OMXOct 18, 2016, 12:00 PM UTC
BusinessMD Anderson Cancer Center and Adaptimmune Form Strategic Alliance to Advance Development of Immunotherapies Targeting Multiple CancersBy Nasdaq OMXSep 26, 2016, 11:30 AM UTC
BusinessAdaptimmune Announces Strategic Manufacturing Agreement with PCT to Support Development of SPEAR® T-cell Therapies Towards CommercializationBy Nasdaq OMXSep 19, 2016, 11:30 AM UTC
BusinessFate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell ImmunotherapiesBy Nasdaq OMXSep 7, 2016, 11:01 AM UTC
BusinessAdaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver CancerBy Nasdaq OMXApr 7, 2016, 1:03 PM UTC
BusinessU.S. Food and Drug Administration Grants Orphan Drug Designation to Adaptimmune’s T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue SarcomaBy Nasdaq OMXMar 30, 2016, 11:40 AM UTC
BusinessAdaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015By Nasdaq OMXMar 17, 2016, 11:56 AM UTC
BusinessFate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016By Nasdaq OMXFeb 25, 2016, 9:01 PM UTC
